Inclusion Criteria:

          -  Diagnosis of Cutaneous T-cell Lymphoma (CTCL) based upon a skin biopsy diagnostic of
             atypical epidermotropism of folliculocentric or epidermotropic T-cells.

          -  Current stage of IA or IB.

          -  Expected survival of greater than or equal to12 months.

          -  Not be on any other investigational device/drug treatment.

          -  Have a sufficient number (i.e., n=4 for first dose cohort in Initial Safety
             Evaluation; n=3 for remainder of subjects) and surface area (> 5 cm2) of CTCL patches
             or plaques for Micro needle array-Doxorubicin (MNA-D) and Micro needle array (MNA)
             application.

          -  Willing to adhere to the instructions of the Investigator and his research team and
             sign an Informed Consent Form prior to entry into the study.

          -  Have the following initial and subsequent pretreatment laboratory parameters:
             granulocytes ≥2,000/mm3; platelets >50,000/mm3; serum creatinine ≤2X the upper limit
             of normal (ULN); AST, ALT, , LDH, Alk phos ≤3X the ULN.Subjects must be ³ 18 years of
             age and must be able to understand the written informed consent/assent document.

          -  Have no evidence of active infection, regardless of the degree of severity or
             localization. Subjects with active infections (whether or not they require antibiotic
             therapy) may be eligible for study participation after complete resolution of the
             infection. Subjects on antibiotic therapy must be off antibiotics before beginning
             treatment.

          -  Not receive any other treatment for CTCL except emollients of subject's choice without
             topical steroids, anti-fungal or antibacterial topical preparations.

          -  Willing to discontinue concomitant medications for CTCL for the duration of their
             study participation, including: high dose topical steroids - 2 week washout; oral
             steroids above 10 mg - 3 week washout; Psoralen + Ultraviolet A light (PUVA) or
             ultraviolet B light (UVB) (including sunbathing, tanning beds, etc.) - 2 week washout;
             extracorporeal photopheresis - 2 week washout; Electron Beam - 2 weeks washout;
             chemotherapeutic agents - 3 week washout; bexarotene capsules or other oral biologics
             - 2 week washout; and topical nitrogen mustard - 2 week washout.

          -  May re-enroll in the study if greater than 4 weeks elapses between courses and if all
             other inclusion/exclusion criteria are met.

        Exclusion Criteria:

          -  Uncontrolled pain.

          -  Known history of autoimmune disease; or active HIV, HTLV-1, and/or hepatitis
             infection.

          -  Pregnant or lactating.

          -  Have sensitivity to drugs that provide local anesthesia.

          -  Have active malignancies with the exception of non-metastatic prostate cancer and
             carcinoma in situ of the skin and cervix.